| HOME >> BIOLOGY >> TECHNOLOGY |
XIANYANG, China, Aug. 14 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced fiscal results for its second quarter ended June 30, 2009.
SUMMARY FINANCIALS
Second Quarter 2009 Results
Q2 2009 Q2 2008 CHANGE
Net Sales $13.2 million $9.4 million +40.6%
Gross Profit $9.7 million $5.4 million +80.5%
Net Income $3.9 million $1.8 million +119.3%
EPS (Fully Diluted) $0.16 $0.08 +100%
Six Month 2009 Results
1H 2009 1H 2008 CHANGE
Net Sales $20.7 million $16.2 million +27.5%
Gross Profit $14.5 million $9.6 million +51.9%
Net Income $5.7 million $3.6 million +58.8%
EPS (Fully Diluted) $0.24 $0.15 +60%
Second Quarter 2009 Financial Results
Revenue for the second quarter of 2009 increased 40.6% to approximately
$13.2 million compared to approximately $9.4 million for the second quarter of
2008. The increase in revenues resulted from Biostar's enhanced marketing and
sales efforts which increased sales of its Xin Aoxing Oleanolic Acid Capsule
("Xin Aoxing Capsule") and Tianqi Dysmenorrhea Capsules ("Tainqi Capsule").
Xin Aoxing Capsule, one of Biostar's flagship OTC products which treats
symptoms common to hepatitis B patients, contributed approximately 67.5% to
total revenues for the quarter, and increased $4.1 million, or 84.1% to $8.9
million, compared to the second quarter of 2008. The increase was primarily
due to market penetration in two additional pro
'/>"/>
| SOURCE Biostar Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved |